Highlights in the Development of New Antiviral Agents

Author: De clercq E.

Source: Mini Reviews in Medicinal Chemistry, Volume 2, Number 2, April 2002 , pp. 163-175(13)

Publisher: Bentham Science Publishers

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

The potential of a large variety of new compounds and new strategies for the treatment of virtually all major virus infections has been addressed. This includes, for the treatment of HIV infections, virus adsorption inhibitors (cosalane derivatives, cyanovirin-N), co-receptor antagonists (TAK-779, AMD3100), viral fusion inhibitors (pentafuside T-20, betulinic acid derivatives), viral uncoating inhibitors (azodicarbonamide), nucleoside / nucleotide reverse transcriptase inhibitors (NRTIs: emtricitabine, amdoxovir, dOTC, d4TMP prodrugs, tenofovir disoproxil fumarate), non-nucleoside reverse transcriptase inhibitors (NNRTIs: thiocarboxanilide UC-781, capravirine, SJ-3366, DPC 083, TMC 125 / R165335), integrase inhibitors (diketo acids), transcription inhibitors (temacrazine, flavopiridol), protease inhibitors (atazanavir, mozenavir, tipranavir) for the treatment of RSV and paramyxovirus infections, viral fusion inhibitors (R170591, VP- 14637, NMS03) for the treatment of picornavirus infections, viral uncoating inhibitors (pleconaril) for the treatment of pesti- (hepaci-, flavi-) virus infections, RNA replicase inhibitors (VP-32947) for the treatment of herpesvirus (HSV, VZV, CMV) infections, DNA polymerase inhibitors (A-5021, L- and Dcyclohexenylguanine) for the treatment of VZV infections, bicyclic furopyrimidine analogues for the treatment of CMV infections, fomivirsen for the treatment of DNA virus infections at large (papilloma-, polyoma-, herpes-, adeno- and poxvirus infections), cidofovir for the treatment of influenza, neuraminidase inhibitors (zanamivir, oseltamivir, RWJ-270201) for the treatment of HBV infections, adefovir dipivoxil for the treatment of HBV and HCV infections, N-glycosylation inhibitors (N-nonyl-deoxynojirimycin) and, finally, IMP dehydrogenase inhibitors and S-adenosylhomocysteine hydrolase inhibitors, for the treatment of various virus infections, including hemorrhagic fever virus infections.

Keywords: antiviral agents; nucleoside reverse transcriptase inhibitors(nrtis); nonnucleoside reverse transcriptase inhibitors(nnr; herpes simplex virus(hsv); cytomegalovirus (cmv); virus adsorption inhibitors; viral fusion inhibitors(hiv); viral uncoating inhibitors(picorna-viruses); viral uncoating inhibitors(hiv); nucleoside reverse transcriptase inhibitors(nrtis)

Language: English

Document Type: Review article

DOI: 10.2174/1389557024605474

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A